drugset / Trial / NCT03316586
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Phase 2
Completed
18 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collabExelixis · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: * Cabozantinib (XL184) * Nivolumab
Timeline
- Start
- 2017-11-30
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |